The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Alternative treatment options for CLL
Klaus Okkenhaug
• 9 Jun 2016
Klaus Okkenhaug, PhD from Babraham Institute, Cambridge, UK discusses alternative options for the treatment for chronic lymphocytic leukemia (CLL). Similar to idelalisib are the SYK inhibitors which are awaiting approval. There are also BTK inhibitors, such as ibrutinib. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
